Clinical evaluation of carcinoembryonic and carbohydrate antigens as cancer biomarkers to monitor palliative chemotherapy in advanced stage gastric cancer

Abbas, Muhammad; Ahmed, Abrar; Khan, Ghulam Jilany; Baig, Mirza Muhammad Faran Ashraf; Naveed, Muhammad; Mikrani, Reyaj; Cao, Tengli; Naeem, Shagufta; Shi, Meiqi; Chen, Dingding

doi:10.1016/j.currproblcancer.2018.08.003

Cited by 24 publications

(10 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Importantly, the 5-year survival rate of patients with EGC can reach more than 90% and the survival rate of patients with metastatic gastric cancer is just only 18% 8 , 9 . Clinically, the sensitivity and specificity of traditional tumor markers such as carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), and CA72-4 are relatively low 10 – 12 . Therefore, it is particularly important and urgent to find minimally invasive or even noninvasive biomarkers that can diagnose GC early.…”

Section: Introductionmentioning

confidence: 99%

Downregulated Expression of linc-ROR in Gastric Cancer and Its Potential Diagnostic and Prognosis Value

Ding

Shi

et al. 2020

Disease Markers

View full text Add to dashboard Cite

Background. Gastric cancer (GC) is one of the global mortality diseases and has a poor prognosis due to the lack of ideal tumor biomarkers. Numerous studies have shown that long noncoding RNAs (lncRNAs) can affect the occurrence and development of cancer through a variety of signaling pathways. The abnormal expression and specificity of lncRNAs in tumors make them potential biomarkers of cancers. Nevertheless, the diagnostic roles of lncRNAs in GC have been poorly understood. So this study focuses on the clinical diagnostic value of lncRNAs in GC. Materials and Methods. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was used to investigate the expression of the linc-ROR (long intergenic noncoding RNA, regulator of reprogramming) in 105 paired GC tissues and adjacent normal tissues. Receiver operating characteristic (ROC) curve and area under the curve (AUC) were established to assess the diagnostic value of linc-ROR. The relationship between expression of linc-ROR and clinicopathological factors of patients with GC was further explored. Kaplan-Meier analysis was performed to evaluate the prognostic value of linc-ROR expression. Results. The linc-ROR expression level was significantly decreased in GC tissues compared with its adjacent nontumor tissues ( n = 105 , P < 0.001 ). We also discovered that linc-ROR was evidently downregulated in 68.6% (72/105) of GC tissues. The AUC’s value of linc-ROR was up to 0.6495, with sensitivity and specificity of 0.7524 and 0.5143, respectively. Intriguingly, the linc-ROR expression levels were obviously associated with tumor differentiation ( P = 0.004 ). Notably, the overall survival rate of GC patients with high expression of linc-ROR was significantly higher than those with low expression. Conclusion. Our data revealed that linc-ROR has clinical potential as a biomarker for the diagnosis of GC and assessment of its prognosis.

show abstract

Section: Introductionmentioning

confidence: 99%

Downregulated Expression of linc-ROR in Gastric Cancer and Its Potential Diagnostic and Prognosis Value

Ding

Shi

et al. 2020

Disease Markers

View full text Add to dashboard Cite

show abstract

“…In the study, they highlighted the benefits of the P10s carbohydratebased vaccine to activate Natural Killer (NK) cells, aid their tumor infiltration, and shape the adaptive responses towards a T helper type 1 (Th1) profile in mouse models. Stage IV metastatic Bca patients had a Th1 cytokine environment marked by considerable IFN-c elevation (Abbas et al 2018). P10s-PADRE immunization was shown to induce the expression of pro-apoptotic antibodies that were caspase-3 dependent leading to ADCC targeting of human Bca cells in vitro, further emphasizing the role of activated NK cells.…”

Section: Breast Cancermentioning

confidence: 95%

Recent advances in carbohydrate-based cancer vaccines

et al. 2019

View full text Add to dashboard Cite

Cancer is a complex multifactorial disease for which many promising therapeutic strategies such as immunotherapy are emerging. Malignant cells frequently express aberrant cell surface carbohydrates, which differentiate them from normal ''healthy'' cells. This characteristic presents a window for the development of synthetic carbohydrate antigen-based cancer vaccines which can be recognized by the immune system and can bring about T cell-dependent immune responses. Antibodies generated against the carbohydrate antigens partake in the inactivation of carbohydrate-decorated cancer cells, by slowing down tumor cell growth and inducing cancer cell apoptosis. Novel synthetic strategies for carbohydrate antigens have led to several synthetic cancer vaccine candidates. In the present review, we describe the latest progress in carbohydrate-based cancer vaccines and their clinical evaluation in various cancers.

show abstract

“…CEA is reported to be overexpressed in many malignancies, such as colorectal cancer (Chi et al, 2020), lung cancer (Grunnet and Sorensen, 2012), gastric cancer (Abbas et al, 2019), and breast cancer (Hing et al, 2020). The CEA level can reflect the occurrence, development, and treatment of tumors.…”

Section: Introductionmentioning

confidence: 99%

A label‐free and signal‐amplifiable assay method for colorimetric detection of carcinoembryonic antigen

Xie

Zhan

et al. 2021

Biotech & Bioengineering

View full text Add to dashboard Cite

In this work, an innovative colorimetric assay method for the determination of carcinoembryonic antigen is developed with aptamer probes utilized as recognition element. DNA hybridization chain reaction is used as signal amplification technique, and peroxidase-mimicking hemin/G-quadruplex-assisted catalytic oxidation of 2,2'azino-bis-3-ethylbenzothiazoline-6-sulfonic acid (ABTS) is deployed as signal reporting mechanism. The detection principle was firstly verified by using gel electrophoresis analysis and absorbance measurements. After condition optimization, a detection limit was theoretically determined as 24.8 ng/ml. Furthermore, the method exhibited good selectivity and satisfactory recovery rates (92.2%-108.6%) in serum samples. Moreover, the sensing scheme is easily extended for the detection of other analytes via similar target-aptamer recognition principle. To sum up, this is an enzyme-and label-free, cost-effective yet signal-amplifiable assay scheme for the determination of tumor markers with promising simplicity and selectivity, practical utility, and potential universality.

show abstract

Clinical evaluation of carcinoembryonic and carbohydrate antigens as cancer biomarkers to monitor palliative chemotherapy in advanced stage gastric cancer

Cited by 24 publications

References 57 publications

Downregulated Expression of linc-ROR in Gastric Cancer and Its Potential Diagnostic and Prognosis Value

Downregulated Expression of linc-ROR in Gastric Cancer and Its Potential Diagnostic and Prognosis Value

Recent advances in carbohydrate-based cancer vaccines

A label‐free and signal‐amplifiable assay method for colorimetric detection of carcinoembryonic antigen

Contact Info

Product

Resources

About